Literature DB >> 6422634

Inactivation of hepatitis B and Hutchinson strain non-A, non-B hepatitis viruses by exposure to Tween 80 and ether.

A M Prince, B Horowitz, B Brotman, T Huima, L Richardson, M C van den Ende.   

Abstract

Titrated stocks of hepatitis B virus and Hutchinson strain non-A, non-B hepatitis virus were diluted in normal serum to contain, respectively, greater than or equal to 10(6) and greater than or equal to 10(4) chimpanzee infectious doses (CID50) per milliliter and exposed to 1% Tween 80 and 20% ether at 4 degrees C for 18 h. After evaporation of the ether, the treated sera were each inoculated into two chimpanzees. The animals remained free of serologic and biochemical evidence of hepatitis during a 6-month follow-up period, and were then shown to be susceptible to infection by challenge with the original untreated inocula. To assess the effect of exposure to Tween 80/ether on coagulation factors, four lots of antihemophilic factor (AHF) concentrate and 2 lots of commercial factor IX concentrate were treated as above. For the AHF concentrate there was an average of 70% recovery of factor VIII procoagulant activity, 93% recovery of factor VIII-related antigen, and 73% recovery of fibronectin opsonin activity and no detectable change in ristocetin cofactor activity or in fibronectin antigen. Crossed immunoelectrophoresis revealed no change in migration rate of fibrinogen, fibronectin, and von Willebrand factor (vWF), although the quantity of fibrinogen was reduced. Factor VIII procoagulant activity and vWF activity remained associated during chromatography on BioGel A15.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6422634     DOI: 10.1111/j.1423-0410.1984.tb00045.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  8 in total

Review 1.  Viral contamination of monoclonal antibody preparations: potential problems and possible solutions.

Authors:  C Harbour; G Woodhouse
Journal:  Cytotechnology       Date:  1990-07       Impact factor: 2.058

2.  Effective virus inactivation and removal by steps of Biotest Pharmaceuticals IGIV production process.

Authors:  Herbert O Dichtelmüller; Eckhard Flechsig; Frank Sananes; Michael Kretschmar; Christopher J Dougherty
Journal:  Results Immunol       Date:  2012-01-16

Review 3.  The chimpanzee model for hepatitis B virus infection.

Authors:  Stefan F Wieland
Journal:  Cold Spring Harb Perspect Med       Date:  2015-06-01       Impact factor: 6.915

Review 4.  Transmission of diseases by blood transfusion.

Authors:  S Seidl; P Kühnl
Journal:  World J Surg       Date:  1987-02       Impact factor: 3.352

5.  [Hepatitis non-A, non-B: epidemiologic, clinical, serologic and morphologic aspects].

Authors:  H P Spichtin
Journal:  Klin Wochenschr       Date:  1985-05-02

Review 6.  The development of virus-free labile blood derivatives--a review.

Authors:  A M Prince; B Horowitz; M S Horowitz; E Zang
Journal:  Eur J Epidemiol       Date:  1987-06       Impact factor: 8.082

Review 7.  The Chimpanzee Model of Viral Hepatitis: Advances in Understanding the Immune Response and Treatment of Viral Hepatitis.

Authors:  Robert E Lanford; Christopher M Walker; Stanley M Lemon
Journal:  ILAR J       Date:  2017-12-01

8.  Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies.

Authors:  Herbert O Dichtelmüller; Lothar Biesert; Fabrizio Fabbrizzi; Rodrigo Gajardo; Albrecht Gröner; Ilka von Hoegen; Juan I Jorquera; Christoph Kempf; Thomas R Kreil; Dominique Pifat; Wendy Osheroff; Gerhard Poelsler
Journal:  Transfusion       Date:  2009-05-20       Impact factor: 3.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.